KR101563757B1 - 복부 대동맥류 치료를 위한 트리아졸로[4,5-ｄ]피리미딘 화합물 - Google Patents
복부 대동맥류 치료를 위한 트리아졸로[4,5-ｄ]피리미딘 화합물 Download PDFInfo
- Publication number
- KR101563757B1 KR101563757B1 KR1020107013193A KR20107013193A KR101563757B1 KR 101563757 B1 KR101563757 B1 KR 101563757B1 KR 1020107013193 A KR1020107013193 A KR 1020107013193A KR 20107013193 A KR20107013193 A KR 20107013193A KR 101563757 B1 KR101563757 B1 KR 101563757B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- treatment
- wall
- thrombus
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title abstract description 37
- 208000002223 abdominal aortic aneurysm Diseases 0.000 title abstract description 18
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- -1 7 - {[2- (3,4- difluorophenyl) cyclopropyl] amino} - 5- (propyl thio) -3 H -1,2,3- triazolo [4,5- d] pyrimidin-3-yl Chemical group 0.000 claims description 6
- 150000002009 diols Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 11
- 239000002464 receptor antagonist Substances 0.000 abstract description 3
- 229940044551 receptor antagonist Drugs 0.000 abstract description 3
- 208000007536 Thrombosis Diseases 0.000 description 46
- 206010002329 Aneurysm Diseases 0.000 description 33
- 241000700159 Rattus Species 0.000 description 30
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 12
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 12
- 208000007474 aortic aneurysm Diseases 0.000 description 11
- 210000000224 granular leucocyte Anatomy 0.000 description 11
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 8
- 210000004177 elastic tissue Anatomy 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 7
- 206010053567 Coagulopathies Diseases 0.000 description 7
- 238000012744 immunostaining Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000010118 platelet activation Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 3
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229940019331 other antithrombotic agent in atc Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- VCVOSERVUCJNPR-UHFFFAOYSA-N cyclopentane-1,2-diol Chemical compound OC1CCCC1O VCVOSERVUCJNPR-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07301616.4 | 2007-12-03 | ||
| EP07301616 | 2007-12-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100099175A KR20100099175A (ko) | 2010-09-10 |
| KR101563757B1 true KR101563757B1 (ko) | 2015-10-27 |
Family
ID=40717966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107013193A Active KR101563757B1 (ko) | 2007-12-03 | 2008-12-02 | 복부 대동맥류 치료를 위한 트리아졸로[4,5-ｄ]피리미딘 화합물 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20100298350A1 (enExample) |
| EP (1) | EP2229172B1 (enExample) |
| JP (1) | JP5701060B2 (enExample) |
| KR (1) | KR101563757B1 (enExample) |
| CN (2) | CN101883565A (enExample) |
| AU (1) | AU2008331984B2 (enExample) |
| BR (1) | BRPI0819458A2 (enExample) |
| CA (1) | CA2707488C (enExample) |
| CY (1) | CY1115760T1 (enExample) |
| DK (1) | DK2229172T3 (enExample) |
| EA (1) | EA201000928A1 (enExample) |
| ES (1) | ES2522317T3 (enExample) |
| HR (1) | HRP20141081T1 (enExample) |
| IL (1) | IL205613A (enExample) |
| MX (1) | MX2010006101A (enExample) |
| MY (1) | MY159656A (enExample) |
| NZ (1) | NZ585513A (enExample) |
| PL (1) | PL2229172T3 (enExample) |
| PT (1) | PT2229172E (enExample) |
| RS (1) | RS53635B1 (enExample) |
| SI (1) | SI2229172T1 (enExample) |
| UA (1) | UA100864C2 (enExample) |
| WO (1) | WO2009072967A1 (enExample) |
| ZA (1) | ZA201003599B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102653539B (zh) * | 2011-03-01 | 2014-09-17 | 秦引林 | 一种抗血小板聚集化合物及其药物组合 |
| CN102924457A (zh) * | 2011-08-12 | 2013-02-13 | 上海恒瑞医药有限公司 | 三唑并嘧啶类衍生物、其制备方法及其用途 |
| EP2750676B1 (en) | 2011-08-30 | 2018-01-10 | University of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000034283A1 (en) | 1998-12-04 | 2000-06-15 | Astrazeneca Ab | Novel triazolo(4,5-d)pyrimidine compounds |
| WO2001092262A1 (en) | 2000-06-02 | 2001-12-06 | Astrazeneca Ab | New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997003084A1 (en) * | 1995-07-11 | 1997-01-30 | Astra Pharmaceuticals Ltd. | New inhibitors of platelet aggregation |
| AR017014A1 (es) * | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
| SE0101932D0 (sv) * | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
| WO2009007675A2 (en) * | 2007-07-11 | 2009-01-15 | Cardoz Ab | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist |
-
2008
- 2008-02-12 UA UAA201005772A patent/UA100864C2/uk unknown
- 2008-12-02 RS RS20140600A patent/RS53635B1/sr unknown
- 2008-12-02 PT PT88573548T patent/PT2229172E/pt unknown
- 2008-12-02 SI SI200831311T patent/SI2229172T1/sl unknown
- 2008-12-02 HR HRP20141081AT patent/HRP20141081T1/hr unknown
- 2008-12-02 JP JP2010536888A patent/JP5701060B2/ja active Active
- 2008-12-02 CN CN2008801189070A patent/CN101883565A/zh active Pending
- 2008-12-02 CN CN201410139401.5A patent/CN103919781A/zh active Pending
- 2008-12-02 DK DK08857354.8T patent/DK2229172T3/da active
- 2008-12-02 BR BRPI0819458 patent/BRPI0819458A2/pt not_active Application Discontinuation
- 2008-12-02 MY MYPI2010002526A patent/MY159656A/en unknown
- 2008-12-02 EP EP08857354.8A patent/EP2229172B1/en active Active
- 2008-12-02 MX MX2010006101A patent/MX2010006101A/es active IP Right Grant
- 2008-12-02 ES ES08857354.8T patent/ES2522317T3/es active Active
- 2008-12-02 PL PL08857354T patent/PL2229172T3/pl unknown
- 2008-12-02 AU AU2008331984A patent/AU2008331984B2/en active Active
- 2008-12-02 EA EA201000928A patent/EA201000928A1/ru unknown
- 2008-12-02 US US12/745,733 patent/US20100298350A1/en not_active Abandoned
- 2008-12-02 NZ NZ585513A patent/NZ585513A/en unknown
- 2008-12-02 WO PCT/SE2008/051386 patent/WO2009072967A1/en not_active Ceased
- 2008-12-02 CA CA2707488A patent/CA2707488C/en not_active Expired - Fee Related
- 2008-12-02 KR KR1020107013193A patent/KR101563757B1/ko active Active
-
2010
- 2010-05-06 IL IL205613A patent/IL205613A/en active IP Right Grant
- 2010-05-20 ZA ZA2010/03599A patent/ZA201003599B/en unknown
-
2014
- 2014-10-30 CY CY20141100893T patent/CY1115760T1/el unknown
-
2015
- 2015-01-15 US US14/597,255 patent/US20150272955A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000034283A1 (en) | 1998-12-04 | 2000-06-15 | Astrazeneca Ab | Novel triazolo(4,5-d)pyrimidine compounds |
| US20070265282A1 (en) | 1998-12-04 | 2007-11-15 | Astrazeneca Ab | Novel compounds |
| WO2001092262A1 (en) | 2000-06-02 | 2001-12-06 | Astrazeneca Ab | New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
Also Published As
| Publication number | Publication date |
|---|---|
| IL205613A0 (en) | 2010-11-30 |
| ES2522317T3 (es) | 2014-11-14 |
| PT2229172E (pt) | 2014-11-03 |
| SI2229172T1 (sl) | 2014-12-31 |
| WO2009072967A1 (en) | 2009-06-11 |
| EP2229172B1 (en) | 2014-09-10 |
| UA100864C2 (uk) | 2013-02-11 |
| HK1148195A1 (en) | 2011-09-02 |
| CA2707488A1 (en) | 2009-06-11 |
| ZA201003599B (en) | 2012-10-31 |
| NZ585513A (en) | 2012-07-27 |
| AU2008331984A1 (en) | 2009-06-11 |
| CN101883565A (zh) | 2010-11-10 |
| MX2010006101A (es) | 2010-10-04 |
| BRPI0819458A2 (pt) | 2015-05-05 |
| KR20100099175A (ko) | 2010-09-10 |
| HRP20141081T1 (hr) | 2015-01-02 |
| JP5701060B2 (ja) | 2015-04-15 |
| CY1115760T1 (el) | 2017-01-25 |
| PL2229172T3 (pl) | 2015-01-30 |
| DK2229172T3 (da) | 2014-11-10 |
| US20150272955A1 (en) | 2015-10-01 |
| EP2229172A4 (en) | 2012-12-26 |
| AU2008331984B2 (en) | 2012-08-16 |
| CA2707488C (en) | 2015-07-28 |
| EP2229172A1 (en) | 2010-09-22 |
| CN103919781A (zh) | 2014-07-16 |
| MY159656A (en) | 2017-01-13 |
| RS53635B1 (sr) | 2015-04-30 |
| IL205613A (en) | 2015-04-30 |
| EA201000928A1 (ru) | 2010-12-30 |
| JP2011505417A (ja) | 2011-02-24 |
| US20100298350A1 (en) | 2010-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hibino et al. | A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts | |
| US7943760B2 (en) | Non-nucleotide composition for inhibiting platelet aggregation | |
| JP5345043B2 (ja) | 組織を修復するための固定具 | |
| Gal | An Overview of SR121463, a Selective Non‐Peptide Vasopressin V2 Receptor Antagonist | |
| CZ20012340A3 (cs) | Kombinace inhibitorů transportu kyčelní ľlučové kyseliny a proteinových inhibitorů cholesteryl-esterového přenosu pro kardiovaskulární indikace | |
| US20060121086A1 (en) | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound | |
| CZ309097A3 (cs) | Synergické kombinace zidovudinu, 1592U89 a 3TC nebo FTC | |
| HUE028008T2 (en) | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | |
| CZ20012341A3 (cs) | Kombinace inhibitorů transferoního proteinu cholesterylesterů a derivátů kyseliny fibrové pro kardiovaskulární indikace | |
| US20120046333A1 (en) | Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis | |
| US20020002145A1 (en) | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | |
| US20150272955A1 (en) | Triazolo[4,5-D]Pyrimidine Compounds For Treatment Of Abdominal Aortic Aneurysms | |
| AU2001238124A1 (en) | Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver | |
| Abrass et al. | Abnormal development of glomerular endothelial and mesangial cells in mice with targeted disruption of the lama3 gene | |
| KR20170103918A (ko) | 폐 고혈압을 위한 병용 요법 | |
| AT500835B1 (de) | Cholinestertransport-protein-mimotop als atherosklerose-medikament | |
| EP2344149A1 (en) | Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis | |
| WO2020092117A2 (en) | Killing senescent cells and treating senescence-associated diseases or disorders using a combination of a bcl inhibitor and an mcl-1 inhibitor | |
| WO2005084652A2 (en) | Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases | |
| HK1148195B (en) | Ticagrelor for treatment of abdominal aortic aneurysms | |
| TWI344366B (en) | Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients | |
| Thomas et al. | Grafting of the major veins: the value of anti-thrombotic drugs to maintain patency | |
| Bentsen et al. | Serum type III procollagen peptide in patients with Pneumocystis carinii infection | |
| WO2022043381A1 (en) | Anti-fibrotic combination | |
| Francischi et al. | Pharmacological Characterization of Sephadex-lnduced Oedema in Rat Paws: Predominant Role of Serotonin and Platelet-Activating Factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20100615 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20131125 Comment text: Request for Examination of Application |
|
| A302 | Request for accelerated examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20141008 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150110 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20150721 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20151021 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20151021 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180918 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20190917 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190917 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200928 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210915 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230918 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240919 Start annual number: 10 End annual number: 10 |